Literature DB >> 9106809

Optimal scoring strategies and weights for the formalin test in rats.

G S Watson1, K J Sufka, T J Coderre.   

Abstract

The formalin test is a well-established model for assessing inflammatory nociceptive processes and analgesic drug effects. Previous research established the validity of an ordinal relationship among three well-defined pain behavior categories used to compute a composite pain score (CPS). However, optimal weights had not been validated. The present research used data from Coderre et al. (1993) and from Sufka and Roach (1996) to determine and validate optimal pain behavior category weights. Based on multiple regression analyses and Pearson correlations, optimal weights of 1 and 2 are proposed for behavior categories 2 and 3, respectively; behavior category 1 is not scored. These results are consistent with the work of Abbott et al. (1995) and Coderre et al. (1993) in that the ordinal relationship among category weights is preserved, and extend previous work by establishing optimal category weights.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9106809     DOI: 10.1016/s0304-3959(96)03299-x

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  22 in total

1.  Tolerance to WIN55,212-2 is delayed in desensitization-resistant S426A/S430A mice.

Authors:  Caitlin M Nealon; Angela N Henderson-Redmond; David E Hale; Daniel J Morgan
Journal:  Neuropharmacology       Date:  2019-01-08       Impact factor: 5.250

2.  The antinociceptive effects of intraplantar injections of 2-arachidonoyl glycerol are mediated by cannabinoid CB2 receptors.

Authors:  J Guindon; J Desroches; P Beaulieu
Journal:  Br J Pharmacol       Date:  2006-12-18       Impact factor: 8.739

3.  The prefrontal cortical endocannabinoid system modulates fear-pain interactions in a subregion-specific manner.

Authors:  Kieran Rea; Fiona McGowan; Louise Corcoran; Michelle Roche; David P Finn
Journal:  Br J Pharmacol       Date:  2018-07-14       Impact factor: 8.739

4.  The endocannabinoid system in the rat dorsolateral periaqueductal grey mediates fear-conditioned analgesia and controls fear expression in the presence of nociceptive tone.

Authors:  W M Olango; M Roche; G K Ford; B Harhen; D P Finn
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

5.  Sex differences in antinociceptive response to Δ-9-tetrahydrocannabinol and CP 55,940 in the mouse formalin test.

Authors:  Rebecca A LaFleur; Ronald P Wilson; Daniel J Morgan; Angela N Henderson-Redmond
Journal:  Neuroreport       Date:  2018-04-11       Impact factor: 1.837

6.  Peripheral antinociceptive effects of inhibitors of monoacylglycerol lipase in a rat model of inflammatory pain.

Authors:  Josée Guindon; Ana Guijarro; Daniele Piomelli; Andrea G Hohmann
Journal:  Br J Pharmacol       Date:  2011-08       Impact factor: 8.739

7.  The antinociceptive effects of nicotinic partial agonists varenicline and sazetidine-A in murine acute and tonic pain models.

Authors:  Shakir D AlSharari; F Ivy Carroll; J Michael McIntosh; M Imad Damaj
Journal:  J Pharmacol Exp Ther       Date:  2012-06-07       Impact factor: 4.030

8.  Morphine-induced antinociception and reward in "humanized" mice expressing the mu opioid receptor A118G polymorphism.

Authors:  Angela N Henderson-Redmond; Matthew B Yuill; Tammy E Lowe; Aaron M Kline; Michael L Zee; Josée Guindon; Daniel J Morgan
Journal:  Brain Res Bull       Date:  2015-10-28       Impact factor: 4.077

9.  c-Jun N terminal kinase signaling pathways mediate cannabinoid tolerance in an agonist-specific manner.

Authors:  Angela N Henderson-Redmond; Caitlin M Nealon; Brian J Davis; Matthew B Yuill; Diana E Sepulveda; Henry L Blanton; Mary K Piscura; Michael L Zee; Chris P Haskins; David J Marcus; Ken Mackie; Josée Guindon; Daniel J Morgan
Journal:  Neuropharmacology       Date:  2019-11-20       Impact factor: 5.250

10.  A role for PPARα in the medial prefrontal cortex in formalin-evoked nociceptive responding in rats.

Authors:  B N Okine; K Rea; W M Olango; J Price; S Herdman; M K Madasu; M Roche; D P Finn
Journal:  Br J Pharmacol       Date:  2014-03       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.